Search

Your search keyword '"Maio V."' showing total 652 results

Search Constraints

Start Over You searched for: Author "Maio V." Remove constraint Author: "Maio V."
652 results on '"Maio V."'

Search Results

3. Risk Factors for Poor Outcomes Among Patients with Extensively Drug-Resistant Tuberculosis (XDR-TB): A Scoping Review

6. MRI- and Histologic-Molecular-Based Radio-Genomics Nomogram for Preoperative Assessment of Risk Classes in Endometrial Cancer

7. Prevalence of Epstein-Barr Virus infection in a cohort of onco-hematologic paediatric patients

11. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

13. POS0118 SMALL FIBER NEUROPATHY EVALUATION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: A SINGLE CENTER STUDY.

14. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

15. Topic: Incisional Hernia — “Difficult case” as specialistic case: real loss of substance, multi recurrences, infections, fistulas, lombocel, burst abdomen, reconstruction of the entire wall

16. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

18. Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy

27. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

28. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

29. CT Features of COVID-19: A Case Report

36. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

45. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

47. Closed Fuel Cycle Waste Treatment Strategy

49. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

50. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

Catalog

Books, media, physical & digital resources